CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Menu
Begin main content
Home About What We Do Programs and Services CADTH Reimbursement Review incobotulinumtoxin A
Back to Programs and Services

CADTH Reimbursement Review

incobotulinumtoxin A

Last Updated: March 1, 2021
Result type: Reports
Project Number: SR0678-000
Product Line: Reimbursement Review

Generic Name: incobotulinumtoxin A

Brand Name: Xeomin

Manufacturer: Merz Pharmaceuticals GMBH

Therapeutic Area: Chronic sialorrhea associated with neurological disorders

Indications: ​For the treatment of chronic sialorrhea associated with neurological disorders in adults.

Manufacturer Requested Reimbursement Criteria1: For the treatment of chronic sialorrhea associated with neurological disorders in adults.

Submission Type: Initial

NOC Status at Filing: Post NOC

Project Status: Received

Companion Diagnostics: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openJanuary 28, 2021
Call for patient/clinician input closedMarch 19, 2021
Submission receivedFebruary 26, 2021
Submission accepted-
Submit Feedback